Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
Status:
Completed
Trial end date:
2017-05-08
Target enrollment:
Participant gender:
Summary
The study was a 8-week, randomized, double-blind, placebo-controlled trial. Berberine (300
mg，three times a day), as an adjuvant therapy has been used on the basis of the
Second-generation antipsychotics（SGAs） monotherapy. All participants were randomly divided
into two groups.Any SGA + berberine (BBR) or any SGA +placebo.Positive and Negative Syndrome
Scale (PANSS) has been used for psychiatric symptoms.The treatment Emergent Symptom
Scale(TESS) has been used for evaluate adverse effects.Glucose and lipid profile,
inflammatory factors，adiponectin，leptin were obtained at 0, 4,8 weeks.